Core Viewpoint - The company, Zhongshe Consulting, reported a revenue of 90.68 million yuan for the year 2025, marking a year-on-year increase of 24.5%. However, it continues to face significant losses, with a net profit attributable to shareholders of -62.64 million yuan, although this represents a notable reduction in losses compared to the previous year [1][3]. Group 1: Revenue and Profit Analysis - The company experienced a revenue increase of 17.84 million yuan compared to the previous year, driven by a nearly doubled number of new orders signed in 2025. However, the revenue growth was limited by project execution cycles and revenue recognition timing, resulting in a lower conversion rate of new orders to revenue [1][2]. - The gross profit margin improved due to strict control over labor costs, with operating costs remaining stable compared to the previous year, leading to a significant increase in gross profit contribution [2]. - The company has been focusing on cost reduction and efficiency improvement, resulting in a decrease in overall period expenses. Notably, R&D expenses dropped significantly as a major project concluded in 2024, while management expenses also saw a decline due to organizational optimization [2]. Group 2: Historical Performance and Future Outlook - Since its listing in November 2021, Zhongshe Consulting has faced a continuous decline in profitability, with net losses recorded for four consecutive years from 2022 to 2025, totaling approximately 200 million yuan in losses [3]. - The company’s non-recurring gains increased due to a reduction in debt restructuring losses, contributing to a decrease in the net loss attributable to shareholders [3].

Core Insights - Boji Pharmaceutical's stock price increased by 2.19% on November 13, reaching 10.74 CNY per share, with a total market capitalization of 4.143 billion CNY [1] - The company has seen a year-to-date stock price increase of 23.19%, with a 7.51% rise over the last five trading days [1] Financial Performance - For the period from January to September 2025, Boji Pharmaceutical reported a revenue of 584 million CNY, representing a year-on-year growth of 5.06% [2] - The net profit attributable to shareholders was 21.9139 million CNY, which reflects a significant decrease of 49.36% compared to the previous year [2] Business Overview - Boji Pharmaceutical specializes in providing preclinical research services, clinical research services, technology transfer services, and consulting services related to new drug development [1] - The revenue composition of the company includes 80.18% from clinical research services, 11.31% from preclinical research services, 6.50% from other consulting services, and 2.02% from supplementary services [1] Shareholder Information - As of September 30, the number of shareholders for Boji Pharmaceutical was 29,600, an increase of 18.91% from the previous period [2] - The average number of circulating shares per shareholder decreased by 15.21% to 9,497 shares [2] Dividend Information - Since its A-share listing, Boji Pharmaceutical has distributed a total of 27.7583 million CNY in dividends, with 12.0783 million CNY distributed over the last three years [3]

Core Insights - Boji Pharmaceutical is a leading provider of new drug research and development outsourcing services in China, established in 2002 and listed on the Shenzhen Stock Exchange in 2015 [1] Group 1: Business Overview - Boji Pharmaceutical offers comprehensive new drug R&D services, including preclinical research, clinical research, technology transfer, and consulting services [1] - The company operates in the pharmaceutical and biotechnology sector, specifically in medical services and R&D outsourcing, with relevant concepts including Helicobacter pylori and hepatitis treatment [1] Group 2: Financial Performance - For Q3 2025, Boji Pharmaceutical reported revenue of 584 million yuan, ranking 16th out of 29 in the industry, significantly lower than the top competitor WuXi AppTec at 32.857 billion yuan [2] - The net profit for the same period was 23.8675 million yuan, placing the company 21st in the industry, again far behind WuXi AppTec's 12.206 billion yuan [2] Group 3: Financial Ratios - As of Q3 2025, Boji Pharmaceutical's debt-to-asset ratio was 33.62%, higher than the previous year's 31.81% and above the industry average of 22.79% [3] - The gross profit margin was 28.83%, down from 32.19% year-on-year and below the industry average of 37.70% [3] Group 4: Leadership and Shareholder Information - The chairman and controlling shareholder, Wang Tingchun, saw his salary decrease from 414,000 yuan in 2023 to 391,000 yuan in 2024 [4] - As of September 30, 2025, the number of A-share shareholders increased by 18.91% to 29,600, while the average number of circulating A-shares held per shareholder decreased by 15.21% [5] Group 5: Business Developments - Clinical business showed stable growth with clinical research service revenue of 290 million yuan and new contract value of 752 million yuan, achieving a business gross margin of 30.6% [5] - Non-clinical business performance varied, with preclinical research service revenue at 40.87 million yuan and other consulting services at 23.49 million yuan [5] - The company has made progress in self-developed projects, including innovative traditional Chinese medicine [5]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for future performance [6]. Core Insights - The company's clinical business shows stable growth, with a revenue of 290 million yuan in H1 2025, reflecting a year-over-year increase of 6.78%. However, the gross margin for this segment has slightly declined [2]. - The non-clinical business performance is mixed, with preclinical research services experiencing a revenue decrease of 2.21% year-over-year, while other consulting services saw a significant increase of 31.79% [3]. - The company has made progress in its self-developed projects, including innovative traditional Chinese medicine and chemical drug candidates, which could enhance profitability if successfully licensed [3]. - The operating cash flow has significantly improved, reaching 21.25 million yuan in H1 2025, a substantial increase of 343.46% compared to the previous year [4]. Summary by Sections Financial Performance - The company reported a total revenue of 361 million yuan for H1 2025, a year-over-year increase of 5.88%. However, the net profit attributable to shareholders decreased by 48.33% to 15.57 million yuan [1]. - The gross margin for clinical services was 30.6%, showing a slight decline of 0.6 percentage points year-over-year [2]. Business Segments - Clinical research services generated 290 million yuan in revenue, with a new contract amount of 752 million yuan, indicating slight growth from the previous year [2]. - Preclinical research services generated 40.87 million yuan, while other consulting services brought in 23.49 million yuan, marking a significant increase [3]. Cash Flow and Operational Efficiency - The net cash flow from operating activities reached 21.25 million yuan, a notable increase from 4.79 million yuan in the same period last year, reflecting improved cash collection efficiency [4]. Profit Forecast and Valuation - The profit forecast for 2025-2026 has been revised downwards, with net profit estimates of 45 million yuan and 66 million yuan respectively. The current stock price corresponds to a P/E ratio of 98 for 2025 [4].

Core Viewpoint - Boji Pharmaceutical's stock closed at 8.89 yuan, down 2.20%, with a rolling PE ratio of 210.74 times, significantly higher than the industry average of 40.82 times [1][2] Company Overview - Boji Pharmaceutical provides comprehensive "one-stop" CRO services for domestic and international pharmaceutical companies and research institutions, focusing on new drug and medical device development [1] - The company's main products include clinical research services, preclinical research services, independent preclinical R&D, and other consulting services [1] Financial Performance - In Q1 2025, the company reported revenue of 139 million yuan, a year-on-year decrease of 17.06%, and a net profit of 3.90 million yuan, down 76.38% [2] - The sales gross margin stood at 30.60% [2] Shareholder Information - As of March 31, 2025, Boji Pharmaceutical had 26,693 shareholders, an increase of 2,742 from the previous period, with an average holding value of 352,800 yuan and an average holding of 27,600 shares per shareholder [1] Industry Comparison - Boji Pharmaceutical ranks 43rd in the medical services industry based on PE ratio, with the industry median at 45.93 times and the average at 40.82 times [1][2] - The company has received several accolades, including being ranked 8th among the top 20 CRO companies in China for 2024 and recognized in various industry events [1]

Core Viewpoint - Boji Pharmaceutical's stock price closed at 8.98 yuan, up 3.82%, with a rolling PE ratio of 212.87, marking a new low in 24 days, and a total market capitalization of 3.441 billion yuan [1] Company Summary - Boji Pharmaceutical provides comprehensive "one-stop" CRO services for domestic and international pharmaceutical companies and research institutions, focusing on new drug and medical device development [1] - The company's main products include clinical research services, preclinical research services, independent preclinical R&D, and other consulting services [1] - Boji Pharmaceutical participated in several significant academic events, enhancing its brand image, and received multiple awards, including being ranked 8th among the top 20 Chinese pharmaceutical CRO companies in 2024 [1] Financial Performance - In the first quarter of 2025, the company reported revenue of 139 million yuan, a year-on-year decrease of 17.06%, and a net profit of 3.9006 million yuan, down 76.38% year-on-year, with a gross profit margin of 30.60% [2] - The company is ranked 43rd in the industry based on its PE ratio, which is significantly higher than the industry average of 40.35 and the median of 47.21 [2]

Core Viewpoint - Boji Pharmaceutical's stock closed at 8.38 yuan, with a PE ratio of 198.65, significantly higher than the industry average of 38.49 [1][2] Company Overview - Boji Pharmaceutical provides comprehensive CRO services for pharmaceutical companies and research institutions, focusing on new drug and medical device development [1] - The company has participated in various academic events, enhancing its brand image and industry connections [1] Financial Performance - For Q1 2025, Boji Pharmaceutical reported revenue of 139 million yuan, a year-on-year decrease of 17.06%, and a net profit of 3.90 million yuan, down 76.38% [2] - The company's gross profit margin stands at 30.60% [2] Market Position - Boji Pharmaceutical ranks 43rd in the medical services industry based on PE ratio, with a total market capitalization of 3.211 billion yuan [1][2] - The company has received several accolades, including being ranked 8th among the top 20 CRO companies in China for 2024 [1]